Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapy
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
Cytotoxic T lymphocyte antigen-4 (CTLA-4) blockade with a monoclonal antibody yields durable responses in a subset of cancer patients and has been approved by the FDA as a standard therapy for late-stage melanoma. We recently identified inducible co-stimulator (ICOS) as a crucial player in the antitumor effects of CTLA-4 blockade. We now show that concomitant CTLA-4 blockade and ICOS engagement by tumor cell vaccines engineered to express ICOS ligand enhanced antitumor immune responses in both quantity and quality and significantly improved rejection of established melanoma and prostate cancer in mice. This study provides strong support for the development of combinatorial therapies incorporating anti-CTLA-4 and ICOS engagement.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures









Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“In addition, the immune monitoring studies performed on the trial highlighted the reverse translational approach and identified ICOS + CD4 T cells as a novel subset of T cells associated with anti-CTLA4 therapy (17,18,171,172).”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [172]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155 · cited 1×
“ICOS is a T cell–specific molecule that belongs to the CD28/CTLA-4 family (Hutloff et al., 1999; Sharpe and Freeman, 2002).”
BackgroundIpilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496 · cited 1×
“Ipilimumab was the first therapy of any kind to show a survival benefit in phase III trials (Hodi et al., 2010; Robert et al., 2011) for patients with advanced melanoma and was approved in March 2011 by the Food and Drug Administration (FDA) as both first and second line therapy for the treatment…”
BackgroundNivolumab plus Ipilimumab in Advanced Melanoma
Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R.-A., Reed, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302369 · Cited by 4,230 · cited 1×
“ELISA of tissue culture supernatant from these cells failed to show the presence of soluble/ (nivolumab) in metastatic melanoma showed an objective response rate of 50% (Wolchok et al., 2013).”
BackgroundEnhancement of Antitumor Immunity by CTLA-4 Blockade
Leach, D. R., Krummel, M. F., & Allison, J. P. (1996) · Science · doi:10.1126/science.271.5256.1734 · Cited by 3,955 · cited 2×
“In a presurgical clinical trial in which patients with localized bladder cancer were treated with ipilimumab, the frequency of T cells expressing inducible co-stimulator (ICOS) was significantly increased both in tumor tissues and peripheral blood of patients (Liakou et al., 2008).”
BackgroundSelf-citationCD28 and CTLA-4 have opposing effects on the response of T cells to stimulation.
Krummel, M. F., & Allison, J. P. (1995) · The Journal of experimental medicine · doi:10.1084/jem.182.2.459 · Cited by 2,245 · cited 1×
“…we showed that inhibitory signals mediated by CTLA-4 were responsible for limiting antitumor responses in a series of mouse models because administration of antibodies blocking the interaction of CTLA-4 with its ligands could result in tumor rejection and long-lived immunity (Leach et al., 1996).”
BackgroundSelf-citationCTLA-4 can function as a negative regulator of T cell activation
Walunas, T. L., Lenschow, D. J., Bakker, C. Y., Linsley, P. S., Freeman, G. J., Green, J. M., Thompson, C. B., & Bluestone, J. A. (1994) · Immunity · doi:10.1016/1074-7613(94)90071-x · Cited by 2,222 · cited 1×
“CD28 co-stimulation is subject to down-regulation by inhibitory molecules such as cytotoxic T lymphocyte antigen-4 (CTLA-4; Walunas et al., 1994; Krummel and Allison, 1995).”
BackgroundSharpe, A. H., & Freeman, G. J. (2002) · Nature Reviews Immunology · doi:10.1038/nri727 · Cited by 1,712 · cited 2×
“ICOS is a T cell–specific molecule that belongs to the CD28/CTLA-4 family (Hutloff et al., 1999; Sharpe and Freeman, 2002).”
BackgroundHarding, F. A., McArthur, J. G., Gross, J. A., Raulet, D. H., & Allison, J. P. (1992) · Nature · doi:10.1038/356607a0 · Cited by 1,559 · cited 1×
“Early T cell activation requires an antigen-specific signal mediated by the TCR plus additional costimulatory signals generated by engagement of molecules such as CD28 with their ligands (Harding et al., 1992).”
BackgroundSelf-citationICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28
Hutloff, A., Dittrich, A. M., Beier, K. C., Eljaschewitsch, B., Kraft, R., Anagnostopoulos, I., & Kroczek, R. A. (1999) · Nature · doi:10.1038/16717 · Cited by 1,482
Simpson, T. R., Li, F., Montalvo-Ortiz, W., Sepulveda, M. A., Bergerhoff, K., Arce, F., Roddie, C., Henry, J. Y., Yagita, H., Wolchok, J. D., et al. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20130579 · Cited by 1,472 · cited 2×
“This effect is potentially driven by heavy infiltration of macrophages in the tumor (Simpson et al., 2013), which is a hallmark of GVAX therapy but not observed in the IVAX model.”
BackgroundSelf-citationvan Elsas, A., Hurwitz, A. A., & Allison, J. P. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.190.3.355 · Cited by 1,020 · cited 1×
“The poorly immunogenic mouse melanoma cell lines B16/F10 and B16/BL6 were obtained from I. Fidler (The University of Texas MD Anderson Cancer Center, Houston, TX) and described previously (van Elsas et al., 1999).”
MethodSelf-citationT-cell co-stimulation through B7RP-1 and ICOS
Yoshinaga, S. K., Whoriskey, J. S., Khare, S. D., Sarmiento, U., Guo, J., Horan, T., Shih, G., Zhang, M., Coccia, M. A., Kohno, T., et al. (1999) · Nature · doi:10.1038/45582 · Cited by 777
Quezada, S. A. (2006) · Journal of Clinical Investigation · doi:10.1172/jci27745 · Cited by 700
Self-citationNovel cancer immunotherapy agents with survival benefit: recent successes and next steps
Sharma, P., Wagner, K., Wolchok, J. D., & Allison, J. P. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3153 · Cited by 642 · cited 1×
“These preclinical studies led to the generation of antibodies to human CTLA-4, ipilimumab and tremelimumab (Sharma et al., 2011).”
BackgroundSelf-citationLiakou, C. I., Kamat, A., Tang, D. N., Chen, H., Sun, J., Troncoso, P., Logothetis, C., & Sharma, P. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806075105 · Cited by 549 · cited 2×
“In a presurgical clinical trial in which patients with localized bladder cancer were treated with ipilimumab, the frequency of T cells expressing inducible co-stimulator (ICOS) was significantly increased both in tumor tissues and peripheral blood of patients (Liakou et al., 2008).”
BackgroundSelf-citationFoster, B. A., Gingrich, J. R., Kwon, E. D., Madias, C. A., & Greenberg, N. M. (1997) · PubMed · Cited by 489
CTLA-4 Blockade with Ipilimumab: Long-term Follow-up of 177 Patients with Metastatic Melanoma
Prieto, P. A., Yang, J. C., Sherry, R. M., Hughes, M. S., Kammula, U. S., White, D. E., Levy, C. L., Rosenberg, S. A., & Phan, G. Q. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1823 · Cited by 477 · cited 1×
“A recent retrospective study of 177 metastatic melanoma patients from the earliest clinical trials of ipilimumab showed an 88-mo median duration of objective responses (Prieto et al., 2012).”
BackgroundCarthon, B. C., Wolchok, J. D., Yuan, J., Kamat, A., Ng Tang, D. S., Sun, J., Ku, G., Troncoso, P., Logothetis, C. J., Allison, J. P., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0569 · Cited by 460 · cited 3×
“This hypothesis was supported by the fact that pretreatment of mice with cyclophosphamide, which preferentially depleted Treg cells, could help improve the efficacy of ICOSL-Ig against poorly immunogenic tumors (Ara et al., 2003).”
BackgroundSelf-citationVonderheide, R. H., LoRusso, P. M., Khalil, M., Gartner, E. M., Khaira, D., Soulieres, D., Dorazio, P., Trosko, J. A., Rüter, J., Mariani, G. L., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0505 · Cited by 301 · cited 2×
“This hypothesis was supported by the fact that pretreatment of mice with cyclophosphamide, which preferentially depleted Treg cells, could help improve the efficacy of ICOSL-Ig against poorly immunogenic tumors (Ara et al., 2003).”
BackgroundThe Inducible Costimulator (ICOS) Is Critical for the Development of Human T H 17 Cells
Paulos, C. M., Carpenito, C., Plesa, G., Suhoski, M. M., Varela-Rohena, A., Golovina, T. N., Carroll, R. G., Riley, J. L., & June, C. H. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3000448 · Cited by 255 · cited 1×
“It has been reported that ICOS signaling in human T cells induced Th17 polarization (Paulos et al., 2010).”
BackgroundThe ICOS/ICOSL Pathway Is Required for Optimal Antitumor Responses Mediated by Anti–CTLA-4 Therapy
Fu, T., He, Q., & Sharma, P. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1138 · Cited by 243 · cited 1×
“Early T cell activation requires an antigen-specific signal mediated by the TCR plus additional costimulatory signals generated by engagement of molecules such as CD28 with their ligands (Harding et al., 1992).”
BackgroundSelf-citationEnhancement of CD8+ T Cell Responses by ICOS/B7h Costimulation
Wallin, J. J., Liang, L., Bakardjiev, A., & Sha, W. C. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.1.132 · Cited by 155 · cited 1×
“For example, it has been shown that ectopic expression of ICOSL could elicit tumor-specific T cell response, but antitumor responses could only be generated in a prophylactic and not a therapeutic setting (Liu et al., 2001; Wallin et al., 2001; Zuberek et al., 2003).”
BackgroundMelanoma Cells Express ICOS Ligand to Promote the Activation and Expansion of T-Regulatory Cells
Martin-Orozco, N., Li, Y., Wang, Y., Liu, S., Hwu, P., Liu, Y.-J., Dong, C., & Radvanyi, L. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1379 · Cited by 142 · cited 1×
“A recent study showed that human melanoma cells expressing high levels of ICOSL facilitated expansion and IL-10 production in the Treg cell population in the setting of high-dose IL-2 treatment (Martin-Orozco et al., 2010).”
BackgroundTumor Vaccines Expressing Flt3 Ligand Synergize with CTLA-4 Blockade to Reject Preimplanted Tumors
Curran, M. A., & Allison, J. P. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3289 · Cited by 132 · cited 1×
“The underlying mechanism of IVAX therapy is likely to be distinct from GVAX and Flt3L-secreting vaccine (FVAX; Curran and Allison, 2009).”
BackgroundSelf-citationLiu, X., Bai, X.-F., Wen, J., Gao, J.-X., Liu, J., Lu, P., Wang, Y., Zheng, P., & Liu, Y. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.194.9.1339 · Cited by 119
Potent activity of soluble B7RP‐1‐Fc in therapy of murine tumors in syngeneic hosts
Ara, G., Baher, A., Storm, N. E., Horan, T., Baikalov, C., Brisan, E., Camacho, R., Moore, A., Goldman, H., Kohno, T., et al. (2002) · International Journal of Cancer · doi:10.1002/ijc.10831 · Cited by 34 · cited 3×
“723 an ICOSL-Ig fusion protein alone failed to induce rejection of poorly immunogenic tumors such as B16 melanoma (Ara et al., 2003; Zuberek et al., 2003).”
BackgroundResultZuberek, K., Ling, V., Wu, P. W., Ma, H., Leonard, J. P., Collins, M. A., & Dunussi‐Joannopoulos, K. (2003) · Cellular Immunology · doi:10.1016/j.cellimm.2003.09.002 · Cited by 23 · cited 2×
“For example, it has been shown that ectopic expression of ICOSL could elicit tumor-specific T cell response, but antitumor responses could only be generated in a prophylactic and not a therapeutic setting (Liu et al., 2001; Wallin et al., 2001; Zuberek et al., 2003).”
BackgroundResult
Cited by
The future of immune checkpoint therapy
Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878
Self-citationA guide to cancer immunotherapy: from T cell basic science to clinical practice
Waldman, A. D., Fritz, J. M., & Lenardo, M. J. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0306-5 · Cited by 4,154
Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential
Sharma, P., & Allison, J. P. (2015) · Cell · doi:10.1016/j.cell.2015.03.030 · Cited by 2,345
“Anti-ICOS antibodies are expected to enter into clinical trials in 2015.”
BackgroundInfluentialSelf-citationDistinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade
Wei, S. C., Levine, J. H., Cogdill, A. P., Zhao, Y., Anang, N.-A. A. S., Andrews, M. C., Sharma, P., Wang, J., Wargo, J. A., Pe’er, D., et al. (2017) · Cell · doi:10.1016/j.cell.2017.07.024 · Cited by 1,302
Self-citationCombination cancer immunotherapy and new immunomodulatory targets
Mahoney, K. M., Rennert, P. D., & Freeman, G. J. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4591 · Cited by 1,294
Metadata
- Authors
- Fan, X., Quezada, S. A., Sepulveda, M. A., Sharma, P., & Allison, J. P.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- University College London (GB)
- Ludwig Center for Cancer Immunotherapy 4 , 5 , and 6
- Memorial Sloan Kettering Cancer Center (US)
- Corresponding author
- Sharma, Padmanee
- Allison, James P.
- Venue
- Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2014-03-31
- Volume
- 211
- Issue
- 4
- Pages
- 715-725
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- PMC
- PMC3978270
- OpenAlex
- W2157041114
- Cited by
- 300
- References
- 28
- Citations by year
- 2026: 7 · 2025: 22 · 2024: 15 · 2023: 26 · 2022: 22 · 2021: 30 · 2020: 31 · 2019: 36 · 2018: 32 · 2017: 27 · 2016: 23 · 2015: 21 · 2014: 8
- FWCI
- 12.72
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- cc-by-nc-sa
- Locations
- The Journal of Experimental Medicine (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- Cancer Research UK (12100)
- National Cancer Institute (R01CA163793, P30CA016672)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- CTLA-4 blockade, ICOS ligand, cancer immunotherapy, melanoma, prostate cancer, tumor cell vaccine, antitumor immunity, combination therapy, immune checkpoint blockade
- MeSH terms
- Animals, Antibodies, Monoclonal, Disease Models, Animal, Immunologic Memory, Immunosuppression Therapy, Immunotherapy, Ligands, Male, Melanoma, Experimental, Prostatic Neoplasms, Signal Transduction, CD4-Positive T-Lymphocytes, Up-Regulation, Cytokines, Lymphocytes, Tumor-Infiltrating, Antigen Presentation, CD8-Positive T-Lymphocytes, Cancer Vaccines, Mice, Inducible T-Cell Co-Stimulator Protein, CTLA-4 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.